These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 19060851

  • 1. Ustekinumab poised to enter the psoriasis market.
    Schmidt C.
    Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
    [No Abstract] [Full Text] [Related]

  • 2. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
    Gandhi M, Alwawi E, Gordon KB.
    Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
    [Abstract] [Full Text] [Related]

  • 3. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
    Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C.
    Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2247-2259. PubMed ID: 28825875
    [Abstract] [Full Text] [Related]

  • 5. Ustekinumab for chronic plaque psoriasis.
    Bartlett BL, Tyring SK.
    Lancet; 2008 May 17; 371(9625):1639-40. PubMed ID: 18486724
    [No Abstract] [Full Text] [Related]

  • 6. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR, Emer J.
    J Drugs Dermatol; 2010 Aug 17; 9(8):947-58. PubMed ID: 20684145
    [Abstract] [Full Text] [Related]

  • 7. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE, Girolomoni G.
    J Eur Acad Dermatol Venereol; 2012 Aug 17; 26 Suppl 5():2-8. PubMed ID: 22758911
    [Abstract] [Full Text] [Related]

  • 8. Safety of biologics in psoriasis.
    Kamata M, Tada Y.
    J Dermatol; 2018 Mar 17; 45(3):279-286. PubMed ID: 29226369
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-12/23 monoclonal antibody for psoriasis.
    Okamoto H, Momohara S.
    N Engl J Med; 2007 May 10; 356(19):2003; author reply 2003. PubMed ID: 17494940
    [No Abstract] [Full Text] [Related]

  • 10. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
    Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C.
    Ann N Y Acad Sci; 2012 Aug 10; 1263():1-12. PubMed ID: 22823582
    [Abstract] [Full Text] [Related]

  • 11. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J, Goldenberg G.
    Cutis; 2017 Feb 10; 99(2):123-127. PubMed ID: 28319618
    [Abstract] [Full Text] [Related]

  • 12. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
    Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, Davis HM.
    J Clin Pharmacol; 2010 Mar 10; 50(3):257-67. PubMed ID: 19934030
    [Abstract] [Full Text] [Related]

  • 13. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
    Bartlett BL, Moody MN, Tyring SK.
    Skin Therapy Lett; 2008 Mar 10; 13(8):1-4. PubMed ID: 19145382
    [Abstract] [Full Text] [Related]

  • 14. Briakinumab for the treatment of plaque psoriasis.
    Traczewski P, Rudnicka L.
    BioDrugs; 2012 Feb 01; 26(1):9-20. PubMed ID: 22077474
    [Abstract] [Full Text] [Related]

  • 15. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV, Exter BP, Steinberg M, Jarvis CI.
    Ann Pharmacother; 2009 Sep 01; 43(9):1456-65. PubMed ID: 19671802
    [Abstract] [Full Text] [Related]

  • 16. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, Leonardi C, PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups.
    Br J Dermatol; 2012 Nov 01; 167(5):1145-52. PubMed ID: 22803615
    [Abstract] [Full Text] [Related]

  • 17. Trial watch: novel biologic for psoriasis shows superiority over current best-seller.
    Nat Rev Drug Discov; 2008 Nov 01; 7(11):880-1. PubMed ID: 18974743
    [No Abstract] [Full Text] [Related]

  • 18. The efficacy of ustekinumab in psoriasis.
    Famenini S, Wu JJ.
    J Drugs Dermatol; 2013 Mar 01; 12(3):317-20. PubMed ID: 23545915
    [Abstract] [Full Text] [Related]

  • 19. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
    Tan JY, Li S, Yang K, Ma B, Chen W, Zha C, Zhang J.
    J Dermatolog Treat; 2011 Dec 01; 22(6):323-36. PubMed ID: 20923370
    [Abstract] [Full Text] [Related]

  • 20. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
    Prescrire Int; 2009 Oct 01; 18(103):202-4. PubMed ID: 19882785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.